Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Editas Medicine, Inc. (EDIT)
|
Add to portfolio |
|
|
|
| Price: |
$27.63
| | Metrics |
| OS: |
81.6
|
M
| |
|
|
| Market cap: |
$2.26
|
B
| |
|
|
|
Net cash:
|
$480
|
M
| |
$5.88
|
per share
|
|
EV:
|
$1.78
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 19.7 | 25.5 | 90.7 | 20.5 | 31.9 | 13.7 | 6.1 | 1.5 |
| Revenue growth | -22.8% | -71.8% | 341.9% | -35.7% | 132.6% | 126.8% | 307.3% | -4470.6% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 |
| Gross profit | 19.7 | 25.5 | 90.7 | 20.5 | 31.9 | 13.7 | 6.1 | 1.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 109.6% |
| Research and development | 175.0 | 142.5 | 158.0 | 96.9 | 90.7 | 83.2 | 57.0 | 18.8 |
| General and administrative | 70.7 | 76.2 | 67.6 | 64.6 | 55.0 | 50.5 | 46.3 | 18.1 |
| EBIT | -226.0 | -193.1 | -134.8 | -140.9 | -113.7 | -119.9 | -97.2 | -35.3 |
| EBIT margin | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% | -2376.3% |
| Pre-tax income | -220.4 | -192.5 | -116.0 | -133.7 | -110.0 | -120.3 | -97.2 | -72.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -220.4 | -192.5 | -116.0 | -133.7 | -110.0 | -120.3 | -97.2 | -73.3 |
| Net margin | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1606.3% | -4932.3% |
| |
| Diluted EPS | ($3.21) | ($2.85) | ($1.98) | ($2.68) | ($2.33) | ($2.98) | ($3.02) | ($28.55) |
| Shares outstanding (diluted) | 68.7 | 67.6 | 58.6 | 50.0 | 47.1 | 40.3 | 32.2 | 2.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|